The DOI matches its Crossref record; 163 of the 166 references it cites were found in a registry or an index.
A decade of exploring the cancer epigenome—biological and translational implications
Open accessAbstract
The past decade has highlighted the central role of epigenetic processes in cancer causation, progression and treatment. Next-generation sequencing is providing a window for visualizing the human epigenome and how it is altered in cancer. This view provides many surprises, including linking epigenetic abnormalities to mutations in genes that control DNA methylation, the packaging and the function of DNA in chromatin, and metabolism. Epigenetic alterations are leading candidates for the development of specific markers for cancer detection, diagnosis and prognosis. The enzymatic processes that control the epigenome present new opportunities for deriving therapeutic strategies designed to reverse transcriptional abnormalities that are inherent to the cancer epigenome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, disruption of chromosomal topology and oncogene insulation may be more generally relevant to methylator phenotypes observed in colorectal and renal cell carcinomas, leukemia and other malignancies28.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies showed that enhanced histone acetylation induced by HDACi allowed the overexpression of genes involved in cell cycle arrest such as cyclin-dependent kinase inhibitors or the growth arrest and DNA damage-inducible protein GADD45 gene family (11, 28, 40, 45-49).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Insulator dysfunction may also be accompanied by promoter silencing events28,29, and by alterations to other pathways affected by 2-HG7,30.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [28]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Among them, novel selective benzamide-based HDAC1/2 inhibitors have been described that exhibit greater than 100-fold selectivity relative to other HDACs (11, 28).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [11]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It has previously been shown that HDAC inhibitors such as SAHA and MS-275 promote cell cycle arrest and apoptosis”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [11]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Among activated genes that subside with pulsed HDACi administration are genes known to be powerful effectors of cell cycle arrest in multiple cell types and may promote apoptosis (11, 50).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [11]
Experimental — accuracy not yet measuredIn the citing paper
“Three general processes have major effects on cancer initiation and progression. First, discrete somatic mutations lead to tumor suppressor loss-of-function and oncoprotein gain-of-function [1]; second, epigenetic alterations change patterns of gene expression [2]; and third, alterations in the tumor microenvironment also lead to broad changes in gene expression [3].”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
DNA methylation patterns and epigenetic memory
Bird, A. (2002) · Genes & Development · doi:10.1101/gad.947102 · Cited by 7,124
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Self-citationA bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis
Gupta, R. A., Shah, N., Wang, K., Kim, J., Horlings, H. M., Wong, D. J., Tsai, M.-C., Hung, T., Argani, P., Rinn, J. L., et al. (2010) · Nature · doi:10.1038/nature08975 · Cited by 5,205
Flagged first, then by citations
3 of the 166 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Allis, C., Jenuwein, T. & Reinberg, D. Epigenetics (ed. Caparros, M.) (Cold Spring Harbor Laboratory Press, 2007).
- Allis, C. D., Jenuwein, T, Reinberg, D. Overview and concepts (Cold Spring Harbor Laboratory Press, New York, 2007).
- Gilbert, M. R. et al. in ASCO Annual Meeting 2011 Abstr. 2006. (University of Texas M. D. Anderson Cancer Center, Chicago, 2011).
Cited by
Sorted by citations
Items 201–300 of 1,001
Epigenetics of Male Infertility: The Role of DNA Methylation
Rotondo, J. C., Lanzillotti, C., Mazziotta, C., Tognon, M. G., & Martini, F. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.689624 · Cited by 197
Management of transitional cell carcinoma of the urinary bladder in dogs: A review
Fulkerson, C. M., & Knapp, D. W. (2015) · The Veterinary Journal · doi:10.1016/j.tvjl.2015.01.017 · Cited by 183
Palma, M. D., & Hanahan, D. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.011 · Cited by 188
CASTILHO, R. M., SQUARIZE, C. H., & Almeida, L. O. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071506 · Cited by 187
Yang, F., Jin, H., Que, B., Chao, Y., Zhang, H., Ying, X., Zhou, Z., Yuan, Z., Su, J., Wu, B., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0755-0 · Cited by 183
Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials
Hontecillas‐Prieto, L., Flores-Campos, R., Silver, A. R., de Álava, E., Hajji, N., & García-Domínguez, D. J. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.578011 · Cited by 186
Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends
Nepali, K., & Liou, J. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00721-x · Cited by 187
Conversion of Stem Cells to Cancer Stem Cells: Undercurrent of Cancer Initiation
Afify, S. M., & Seno, M. (2019) · Cancers · doi:10.3390/cancers11030345 · Cited by 188
Genetic alterations in hepatocellular carcinoma: An update
Niu, Z.-S., Niu, X.-J., & Wang, W. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i41.9069 · Cited by 193
Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer
Díaz‐Lagares, Á., Crujeiras, A. B., López-Serra, P., Soler, M., Setién, F., Goyal, A., Sandoval, J., Hashimoto, Y., Martínez‐Cardús, A., Gómez, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608585113 · Cited by 179
Marek, M., Kannan, S., Hauser, A.-T., Moraes Mourão, M., Caby, S., Cura, V., Stolfa, D. A., Schmidtkunz, K., Lancelot, J., Andrade, L., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003645 · Cited by 173
Cancers with wrong HATs: the impact of acetylation
Di Cerbo, V., & Schneider, R. (2013) · Briefings in Functional Genomics · doi:10.1093/bfgp/els065 · Cited by 178
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine
Ogino, S., Fuchs, C. S., & Giovannucci, E. L. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.46 · Cited by 180
Methylated circulating tumor DNA in blood: power in cancer prognosis and response
Warton, K., Mahon, K. L., & Samimi, G. (2016) · Endocrine Related Cancer · doi:10.1530/erc-15-0369 · Cited by 179
The Transcription Factor FOXM1 (Forkhead box M1)
Wierstra, I. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-407173-5.00004-2 · Cited by 180
Genomic Imprinting: Insights From Plants
Gehring, M. A. (2013) · Annual Review of Genetics · doi:10.1146/annurev-genet-110711-155527 · Cited by 176
DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer
Müller, D., & Győrffy, B. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188722 · Cited by 185
An integrative ENCODE resource for cancer genomics
Zhang, J., Lee, D., Dhiman, V., Jiang, P., Xu, J., McGillivray, P., Yang, H., Liu, J., Meyerson, W., Clarke, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14743-w · Cited by 172
Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies
Morrow, J. J., & Khanna, C. (2015) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2015013713 · Cited by 176
Widschwendter, M., Zikán, M., Wahl, B., Lempiäinen, H., Paprotka, T., Evans, I., Jones, A., Ghazali, S., Reisel, D., Eichner, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0500-7 · Cited by 176
Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal
Erenpreisa, J. A., & Cragg, M. S. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-92 · Cited by 177
Absence of RIPK3 predicts necroptosis resistance in malignant melanoma
Geserick, P., Wang, J., Schilling, R., Horn, S., Harris, P. A., Bertin, J., Gough, P. J., Feoktistova, M., & Leverkus, M. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.240 · Cited by 172
HDAC inhibitors and immunotherapy; a double edged sword?
Kroesen, M., Gielen, P. R., Brok, I. C., Armandari, I., Hoogerbrugge, P. M., & Adema, G. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2289 · Cited by 168
Asada, K., Nakajima, T., Shimazu, T., Yamamichi, N., Maekita, T., Yokoi, C., Oda, I., Ando, T., Yoshida, T., Nanjo, S., et al. (2014) · Gut · doi:10.1136/gutjnl-2014-307094 · Cited by 168
A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype
Serra, R. W., Fang, M., Park, S. M., Hutchinson, L., & Green, M. R. (2014) · eLife · doi:10.7554/elife.02313 · Cited by 172
Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer
He, S., Dong, G., Li, Y., Wu, S., Wang, W., & Sheng, C. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201915896 · Cited by 166
Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma
Ma, R., Zhang, W., Tang, K., Zhang, H., Zhang, Y., Li, D., Li, Y., Xu, P., Luo, S., Cai, W., et al. (2013) · Nature Communications · doi:10.1038/ncomms3508 · Cited by 168
A panel of genes methylated with high frequency in colorectal cancer
Mitchell, S. M., Ross, J. P., Drew, H. R., Ho, T., Brown, G. S., Saunders, N. F. W., Duesing, K., Buckley, M. J., Dunne, R. A., Beetson, I., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-54 · Cited by 162
Wong, C., Wei, L., Law, C., Ho, D. W., Tsang, F. H., Au, S. L., Sze, K. M., Lee, J. M., Wong, C. C., & Ng, I. O. (2015) · Hepatology · doi:10.1002/hep.28304 · Cited by 168
Liu, Z., Xie, Y., Xiong, Y., Liu, S., Qiu, C., Zhu, Z., Mao, H., Yu, M., & Wang, X. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.020 · Cited by 165
Pharmacogenomics of Human Uridine Diphospho-Glucuronosyltransferases and Clinical Implications
Guillemette, C., Lévesque, É., & Rouleau, M. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.126 · Cited by 162
DNA Hypomethylating Drugs in Cancer TherapyPreprint
Sato, T., Issa, J. J., & Kropf, P. L. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026948 · Cited by 169
Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns
Sproul, D., Kitchen, R. R., Nestor, C. E., Dixon, J. M., Sims, A. H., Harrison, D. J., Ramsahoye, B. H., & Meehan, R. R. (2012) · Genome Biology · doi:10.1186/gb-2012-13-10-r84 · Cited by 191
Connolly, R. M., Li, H., Jankowitz, R. C., Zhang, Z., Rudek, M. A., Jeter, S. C., Slater, S. A., Powers, P., Wolff, A. C., Fetting, J. H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1729 · Cited by 163
Self-citationDNA methylation based biomarkers: Practical considerations and applications
Kit, A. H., Nielsen, H. M., & Tost, J. (2012) · Biochimie · doi:10.1016/j.biochi.2012.07.014 · Cited by 163
Mendelian Disorders of the Epigenetic Machinery: Tipping the Balance of Chromatin States
Fahrner, J. A., & Bjornsson, H. T. (2014) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090613-094245 · Cited by 166
Harnessing the potential of epigenetic therapy to target solid tumors
Ahuja, N., Easwaran, H., & Baylin, S. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69736 · Cited by 165
Self-citationHistone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis
Yuan, H., Li, N., Fu, D., Ren, J., Hui, J., Peng, J., Liu, Y., Qiu, T., Jiang, M., Pan‐Hammarström, Q., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94292 · Cited by 165
Developmental reprogramming of cancer susceptibility
Walker, C. L., & Ho, S. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3220 · Cited by 160
Gastric cancer: somatic genetics as a guide to therapy
Zhang, X., & Zhang, P.-Y. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-104171 · Cited by 159
Urine biomarkers in bladder cancer — current status and future perspectives
Maas, M., Todenhöfer, T., & Black, P. C. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00773-8 · Cited by 159
Molecular mechanism for USP7-mediated DNMT1 stabilization by acetylation.
Cheng, J., Yang, H., Fang, J., Ma, L., Gong, R., Wang, P., Li, Z., & Xu, Y. (2015) · Nature Communications · doi:10.1038/ncomms8023 · Cited by 158
Arechederra, M., Daian, F., Yim, A., Bazai, S. K., Richelme, S., Dono, R., Saurin, A. J., Habermann, B. H., & Maina, F. (2018) · Nature Communications · doi:10.1038/s41467-018-05550-5 · Cited by 221
Katoh, M. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1444 · Cited by 159
Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer
Asangani, I. A., Ateeq, B., Cao, Q., Dodson, L. M., Pandhi, M. B., Kunju, L. P., Mehra, R., Lonigro, R. J., Siddiqui, J., Palanisamy, N., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.10.008 · Cited by 158
Biology and treatment of renal tumours in childhood
Brok, J. S., Treger, T. D., Gooskens, S. L. M., van den Heuvel‐Eibrink, M. M., & Pritchard‐Jones, K. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.005 · Cited by 160
Potential functional roles of DNA demethylation intermediates
Song, C.-X., & He, C. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.07.003 · Cited by 154
Queirós, A. C., Villamor, N., Clot, G., Martínez‐Trillos, A., Kulis, M., Navarro, A., Penas, E. M. M., Jayne, S., Majid, A., Richter, J., et al. (2014) · Leukemia · doi:10.1038/leu.2014.252 · Cited by 158
Histone modifications and cancer: biomarkers of prognosis?
Chervona, Y., & Costa, M. (2012) · Europe PMC (PubMed Central) · Cited by 155
Wu, H., Wu, X., Shen, L., & Zhang, Y. (2014) · Nature Biotechnology · doi:10.1038/nbt.3073 · Cited by 157
Intratumoral Heterogeneity: From Diversity Comes Resistance
Pribluda, A., de la Cruz, C. C., & Jackson, E. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1213 · Cited by 160
Tang, Y., Pan, J., Huang, S., Peng, X., Zou, X., Luo, Y., Ren, D., Zhang, X., Li, R., He, P., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0813-4 · Cited by 150
Helicobacter pylori Causes Epigenetic Dysregulation of FOXD3 to Promote Gastric Carcinogenesis
Cheng, A. S. L., Li, M. S. M., Kang, W., Cheng, V. Y. Y., Chou, J., Lau, S. S., Go, M. Y. Y., Lee, C. C., Ling, T. K. �., Ng, E. K. O., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.10.002 · Cited by 150
Di, L. J., Byun, J. S., Wong, M., Wakano, C., Taylor, T. J., Bilke, S., Baek, S., Hunter, K. W., Yang, H. H., Lee, M. Y., et al. (2013) · Nature Communications · doi:10.1038/ncomms2438 · Cited by 155
Cancer epigenetics drug discovery and development: the challenge of hitting the mark
Campbell, R. M., & Tummino, P. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71605 · Cited by 157
Cancer Epigenetics: An Overview
Targa, F. R. (2022) · Archives of Medical Research · doi:10.1016/j.arcmed.2022.11.003 · Cited by 171
Entinostat: a promising treatment option for patients with advanced breast cancer
Connolly, R. M., Rudek, M. A., & Piekarz, R. (2017) · Future Oncology · doi:10.2217/fon-2016-0526 · Cited by 148
Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia
Oakes, C. C., Claus, R., Gu, L., Assenov, Y., Hüllein, J., Zucknick, M., Bieg, M., Brocks, D., Bogatyrova, O., Schmidt, C. R., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0349 · Cited by 153
Rendeiro, A. F., Schmidl, C., Strefford, J. C., Walewska, R., Davis, Z., Farlik, M., Oscier, D., & Bock, C. (2016) · Nature Communications · doi:10.1038/ncomms11938 · Cited by 146
Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia
Guièze, R., & Wu, C. J. (2015) · Blood · doi:10.1182/blood-2015-02-585042 · Cited by 151
Wen, L., Li, J., Guo, H., Liu, X., Zheng, S., Zhang, D., Zhu, W., Qu, J., Guo, L., Du, D., et al. (2015) · Cell Research · doi:10.1038/cr.2015.126 · Cited by 147
Takai, H., Masuda, K., Sato, T., Sakaguchi, Y., Suzuki, T., Suzuki, T., Koyama‐Nasu, R., Nasu‐Nishimura, Y., Katou, Y., Ogawa, H., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.071 · Cited by 151
Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma
Carter, D. R., Murray, J. E., Cheung, B. B., Gamble, L. D., Koach, J., Tsang, J., Sutton, S. K., Kalla, H., Syed, S., Gifford, A. J., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab1803 · Cited by 147
Zhang, Y. W., Wang, Z., Xie, W., Cai, Y., Xia, L., Easwaran, H., Luo, J., Yen, R.-W. C., Li, Y., & Baylin, S. B. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.12.013 · Cited by 148
Self-citationThe molecular feature of macrophages in tumor immune microenvironment of glioma patients
Zhang, H., Luo, Y., Wu, W., Zhang, L., Wang, Z., Dai, Z., Feng, S., Cao, H., Cheng, Q., & Liu, Z. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.019 · Cited by 150
Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs
Brien, G. L., Valerio, D. G., & Armstrong, S. A. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.007 · Cited by 155
Chango, A., & Pogribny, I. (2015) · Nutrients · doi:10.3390/nu7042748 · Cited by 144
Editing the Epigenome: Reshaping the Genomic Landscape
Holtzman, L., & Gersbach, C. A. (2018) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021632 · Cited by 147
Epigenetic flexibility in metabolic regulation: disease cause and prevention
Kirchner, H., Osler, M. E., Krook, A., & Zierath, J. R. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2012.11.008 · Cited by 143
Targeting DNA Methylation with Small Molecules: What’s Next?
Erdmann, A., Halby, L., Fahy, J., & Arimondo, P. B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500843d · Cited by 149
Super-enhancer function and its application in cancer targeted therapy
Tang, F., Yang, Z., Tan, Y., & Li, Y. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0108-z · Cited by 145
Piña‐Sánchez, P., Chávez‐González, A., Tachiquín, M. E. R., Vadillo, E., Monroy-García, A., Montesinos, J. J., Álvarez, R. G., de la Barrera, M. G., & Mayani, H. (2021) · Cancer Control · doi:10.1177/10732748211038735 · Cited by 165
Singh, A. K., Arya, R. K., Maheshwari, S., Singh, A., Meena, S., Pandey, P., Dormond, O., & Datta, D. B. (2014) · International Journal of Cancer · doi:10.1002/ijc.28804 · Cited by 145
Asmar, F., Punj, V., Christensen, J. F., Pedersen, M. T., Pedersen, A., Nielsen, A. B., Hother, C. E., Ralfkiær, U., Brown, P. D. N., Ralfkiaer, E. M., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.088740 · Cited by 147
PIWI Proteins and PIWI-Interacting RNA: Emerging Roles in Cancer
Han, Y.-N., Li, Y., Xia, S., Zhang, Y.-Y., Zheng, J.-H., & Li, W. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000484541 · Cited by 144
Using tumour phylogenetics to identify the roots of metastasis in humans
Naxerova, K., & Jain, R. K. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.238 · Cited by 144
Choi, J., Zhang, T., Vu, A. H., Ablain, J., Makowski, M. M., Colli, L. M., Xu, M., Hennessey, R. C., Yin, J., Rothschild, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16590-1 · Cited by 143
Zhao, A., Zhou, H., Yang, J., Li, M., & Niu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01342-6 · Cited by 153
Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 138
Valente, S., Liu, Y., Schnekenburger, M., Zwergel, C., Cosconati, S., Gros, C., Tardugno, M., Labella, D., Florean, C., Minden, S., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4012627 · Cited by 138
Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island
Wasserkort, R., Kalmár, A., Valcz, G., Spisák, S., Krispin, M., Tóth, K., Tulassay, Z., Sledziewski, A. Z., & Molnar, B. A. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-398 · Cited by 138
Single-molecule decoding of combinatorially modified nucleosomes
Shema, E., Jones, D. R., Shoresh, N., Donohue, L., Ram, O., & Bernstein, B. (2016) · Science · doi:10.1126/science.aad7701 · Cited by 141
Precision oncology in the age of integrative genomics
Kumar‐Sinha, C., & Chinnaiyan, A. M. (2018) · Nature Biotechnology · doi:10.1038/nbt.4017 · Cited by 138
Epigenetic and Transcriptional Alterations in Human Adipose Tissue of Polycystic Ovary Syndrome
Kokosar, M., Benrick, A., Perfilyev, A., Fornes, R., Nilsson, E., Maliqueo, M., Behre, C. J., Sazonova, A., Ohlsson, C., Ling, C., et al. (2016) · Scientific Reports · doi:10.1038/srep22883 · Cited by 137
O-GlcNAc signaling in cancer metabolism and epigenetics
Singh, J. P., Zhang, K., Wu, J., & Yang, X. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.04.014 · Cited by 138
Paskeh, M. D. A., Mirzaei, S., Ashrafizadeh, M., Zarrabi, A., & Sethi, G. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s336858 · Cited by 140
Loss of 5-hydroxymethylcytosine in cancer: Cause or consequence?
Ficz, G., & Gribben, J. G. (2014) · Genomics · doi:10.1016/j.ygeno.2014.08.017 · Cited by 135
Arai, E., Chiku, S., Mori, T., Gotoh, M., Nakagawa, T., Fujimoto, H., & Kanai, Y. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs177 · Cited by 134
Bots, M. L., Verbrugge, I., Martin, B. P., Salmon, J. M., Ghisi, M., Baker, A., Stanley, K. L., Shortt, J., Ossenkoppele, G. J., Zuber, J. A., et al. (2014) · Blood · doi:10.1182/blood-2013-03-488114 · Cited by 129
Genomic insights into cancer-associated aberrant CpG island hypermethylation
Sproul, D., & Meehan, R. R. (2013) · Briefings in Functional Genomics · doi:10.1093/bfgp/els063 · Cited by 135
Ionizing Radiation-Induced Epigenetic Modifications and Their Relevance to Radiation Protection
Belli, M., & Tabocchini, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21175993 · Cited by 138
Interplay between Epigenetics and Genetics in Cancer
Choi, J. D., & Lee, J.-S. (2013) · Genomics & Informatics · doi:10.5808/gi.2013.11.4.164 · Cited by 131
Epigenetics of cancer stem cells: Pathways and therapeutics
Shukla, S., & Meeran, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.09.017 · Cited by 135
Advances in epigenetic therapeutics with focus on solid tumors
Jin, N. Y., George, T. L., Otterson, G. A., Verschraegen, C. F., Wen, H., Carbone, D. P., Herman, J. G., Bertino, E. M., & He, K. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01069-7 · Cited by 135
Liu, M., Thomas, S. L., DeWitt, A. K., Zhou, W., Madaj, Z. B., Ohtani, H., Baylin, S. B., Liang, G., & Jones, P. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3953 · Cited by 127
Self-citationMo, S., Li, Y., Wang, D., Han, L., Zhou, S., Wang, H., Dai, W., Wang, Y., Luo, W., Wang, R., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.0425 · Cited by 135
Quantitative Analysis of the DNA Methylation Sensitivity of Transcription Factor Complexes
Kribelbauer, J. F., Laptenko, O., Chen, S., Martini, G. D., Freed-Pastor, W. A., Prives, C. L., Mann, R. S., & Bussemaker, H. J. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.069 · Cited by 130
Biomarkers for detecting colorectal cancer non-invasively: DNA, RNA or proteins?
Loktionov, A. S. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i2.124 · Cited by 132
YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6
Chen, S., Lǚ, K., Hou, Y., You, Z., Shu, C., Wei, X., Wu, T., Shi, N., Zhang, G., Wu, J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006020 · Cited by 132
Epigenetic Aging Signatures Are Coherently Modified in Cancer
Lin, Q., & Wagner, W. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005334 · Cited by 129
Metadata
- Authors
- Baylin, S. B., & Jones, P. A.
- Affiliations
- Johns Hopkins University (US)
- University of Southern California (US)
- Corresponding author
- Baylin, Stephen B.
- Jones, Peter A.
- Venue
- Nature Reviews Cancer
- Published
- 2011-09-23
- Volume
- 11
- Issue
- 10
- Pages
- 726-734
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3307543
- OpenAlex
- W2041686632
- Cited by
- 2,871
- References
- 166
- Citations by year
- 2026: 105 · 2025: 107 · 2024: 130 · 2023: 148 · 2022: 179 · 2021: 207 · 2020: 175 · 2019: 209 · 2018: 192 · 2017: 233 · 2016: 241 · 2015: 248 · 2014: 288 · 2013: 231 · 2012: 171
- FWCI
- 20.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Entertainment Industry Foundation
- National Institutes of Health
- National Cancer Institute (R01CA043318, R37CA082422)
- National Institute of Environmental Health Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- cancer epigenome, DNA methylation, chromatin, epigenetic therapy, tumor markers, cancer diagnosis and prognosis, tumor progression, DNA packaging, epigenetic enzymes, cancer metabolism, epigenetic mutations
- MeSH terms
- Animals, Humans, Neoplasms, Genome, Epigenesis, Genetic, History, 20th Century, History, 21st Century, Translational Research, Biomedical, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
